STAT

Some flu vaccines may work better than others — but guidance to the public is scant

Four companies offered a total of 12 different influenza vaccines this past year. But not all are created equal.
Flublok, made by Protein Sciences, was recently acquired by Sanofi.

Last fall some people in the know about influenza science got picky when it came time to get their flu shots.

They didn’t want to roll up their sleeve for any old vaccine on offer at their doctor’s office or workplace clinic. They sought specific products, the ones licensed for older adults that contain a performance-boosting compound called an adjuvant or more notably one of the two brands of vaccine not made — as most flu vaccines are — in eggs.

“My colleagues who are over age 65, everybody wanted basically the Fluad or the Protein Sciences vaccine, Flublok,” said Dr. Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota. (Fluad, made by Seqirus, contains an adjuvant;

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks